Cancer vaccines for hematologic malignancies

Cancer Control

Volumn 9, Issue 2, 2002, Pages 138-151

  Borrello, Ivan M ^a   Sotomayor, Eduardo M ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BCR ABL PROTEIN; CANCER VACCINE; CORYNEBACTERIUM PARVUM VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MONTANIDE; PROTEIN PR1; QS 21; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; MOLECULAR BIOLOGY; NONHUMAN; VACCINATION;

EID: 0036240030     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900206     Document Type: Article

References (98)

1. Augmentation of host immune responses to cancer: Overcoming the barrier of tumor antigen-specific T-cell tolerance
2. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
3. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial
4. Adoptive immunotherapy with donor lymphocyte transfusions
5. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
6. Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis
7. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: The role of cytotoxic T lymphocytes
8. Bacteria and cancer: Antagonisms and benefits
9. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients
10. Human tumor antigens recognized by T lymphocytes
11. A new era for cancer immunotherapy based on the genes that encode cancer antigens
12. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
13. Enhancement of antitumor immunity by CTLA-4 blockade
14. Tumor immunology: The glass is half full
15. Cancer vaccines
16. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
17. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene
18. Serological identification of human tumor antigens
19. Oncogenic proteins as tumor antigens
20. CML vaccines as a paradigm of the specific immunotherapy of cancer
21. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein
22. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
23. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA
24. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation
25. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pm1/RAR alpha present in acute promyelocytic leukemia cells
26. The history of the development of vaccines for the treatment of lymphoma
27. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: A therapeutic target
28. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
29. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone
30. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies
31. Idiotype vaccination against murine B cell lymphoma: Humoral and cellular requirements for the full expression of antitumor immunity
32. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial
33. Human tumor antigens recognized by T cells
34. A non-apeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
35. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
36. Genes encoding tumor-specific antigens are expressed in human myeloma cells
37. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia
38. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units
39. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
40. Wilms tumor gene expression in acute myeloid leukemias
41. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide
42. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1
43. WT1-specific serum antibodies in patients with leukemia
44. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient
45. Human tumor antigens are ready to fly
46. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease
47. Epstein-Barr virus and lymphoma
48. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
49. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
50. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
51. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs
52. When magic bullets miss their mark
53. Cancer vaccines: A road map for the next decade
54. T cells and tumours
55. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
56. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression
57. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
58. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
59. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity
60. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response
61. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
62. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40
63. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
64. Modulation of antigen-presenting cells (APCs) function by aminobisphosphonates enhances T-cell priming and prevents tumor-induced T-cell tolerance
65. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma
66. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
67. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies
68. Idiotype-specific T lymphocytes in monoclonal gammopathies: Evidence for the presence of CD4+ and CD8+ subsets
69. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome
70. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells
71. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy
72. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma
73. Donor-recipient polymorphism of the proteinase 3 gene: A potential target for T-cell alloresponses to myeloid leukemia
74. Lack of T-cell-mediated recognition of the fusion region of the pm1/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients
75. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
76. Alternative splicing of RNAs transcribed from the human abgene and from the bcr-abl fused gene
77. New strategies for enhancing the immunogenicity of tumors
78. Viral oncolysis: Increased immunogenicity of host cell antigen associated with influenza virus
79. Genetically engineered tumor vaccines
80. Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
81. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells
82. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines
83. Dendritic cells and the control of immunity
84. The distinct surface of human blood dendritic cells, as observed after an improved isolation method
85. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro
86. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
87. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy
88. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
89. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells
90. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
91. The in-vitro generation of dendritic cells from blast cells in acute leukaemia
92. Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia
93. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: A feasibility study
94. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
95. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
96. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines
97. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease
98. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation